<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1111/jgh.16033</dc:identifier><dc:language>eng</dc:language><dc:creator>Lanas, Angel</dc:creator><dc:creator>Andrews, Jane M</dc:creator><dc:creator>Lau, James</dc:creator><dc:creator>Toruner, Murat</dc:creator><dc:creator>Bromley, Susan E</dc:creator><dc:creator>Gralnek, Ian M</dc:creator><dc:title>Management of iron-deficiency anemia following acute gastrointestinal hemorrhage: A narrative analysis and review</dc:title><dc:identifier>ART-2023-131249</dc:identifier><dc:description>Many patients experiencing acute gastrointestinal bleeding (GIB) require iron supplemen-tation to treat subsequent iron deficiency (ID) or iron-deficiency anemia (IDA). Guidelinesregarding management of these patients are lacking. We aimed to identify areas of unmetneed in patients with ID/IDA following acute GIB in terms of patient management andphysician guidance. We formed an international working group of gastroenterologists toconduct a narrative review based on PubMed and EMBASE database searches (fromJanuary 2000 to February 2021), integrated with observations from our own clinical expe-rience. Published data on this subject are limited and disparate, and those relating topost-discharge outcomes, such as persistent anemia and re-hospitalization, are particularlylacking. Often, there is no post-discharge follow-up of these patients by a gastroenterolo-gist. Acute GIB-related ID/IDA, however, is a prevalent condition both at the time of hos-pital admission and at hospital discharge and is likely underdiagnosed and undertreated.Despite limited data, there appears to be notable variation in the prescribing of intravenous(IV)/oral iron regimens. There is also some evidence suggesting that, compared with oraliron, IV iron may restore iron levels faster following acute GIB, have a better tolerabilityprofile, and be more beneficial in terms of quality of life. Gaps in patient care exist inthe  management  of  acute  GIB-related  ID/IDA,  yet  further  data  from  largepopulation-based studies are needed to confirm this. We advocate the formulation ofevidence-based guidance on the use of iron therapies in these patients, aiding a more stan-dardized best-practice approach to patient care.</dc:description><dc:date>2023</dc:date><dc:source>http://zaguan.unizar.es/record/121012</dc:source><dc:doi>10.1111/jgh.16033</dc:doi><dc:identifier>http://zaguan.unizar.es/record/121012</dc:identifier><dc:identifier>oai:zaguan.unizar.es:121012</dc:identifier><dc:identifier.citation>Journal of Gastroenterology and Hepatology (Australia) 38, 1 (2023), 23-33</dc:identifier.citation><dc:rights>by-nc</dc:rights><dc:rights>http://creativecommons.org/licenses/by-nc/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>